Senzime Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Senzime heeft een totaal eigen vermogen van SEK285.0M en een totale schuld van SEK0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk SEK355.2M en SEK70.2M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

SEK 0

Schuld

Rente dekkingsratio	n/a
Contant	SEK 50.24m
Aandelen	SEK 285.04m
Totaal verplichtingen	SEK 70.21m
Totaal activa	SEK 355.25m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( SEK98.2M ) 6YC } overtreffen de korte termijn passiva ( SEK27.6M ).

Langlopende schulden: De kortetermijnactiva 6YC ( SEK98.2M ) overtreffen de langetermijnschulden ( SEK42.6M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 6YC is schuldenvrij.

Schuld verminderen: 6YC had 5 jaar geleden geen schulden.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: 6YC heeft minder dan een jaar aan cash runway op basis van de huidige vrije kasstroom.

Voorspelling contante baan: 6YC heeft minder dan een jaar aan kasmiddelen als de vrije kasstroom blijft dalen met historische percentages van 30 % per jaar.

Senzime Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Chairman of the Board recently bought €106k worth of stock

New minor risk - Profitability

Third quarter 2024 earnings released: kr0.26 loss per share (vs kr0.33 loss in 3Q 2023)

Senzime AB (publ) to Report Q1, 2025 Results on May 07, 2025

Senzime Successfully Unveils Next-Generation TetraGraph Quantitative Train-Of-Four Monitor at ANESTHESI Technology 2024

Senzime to Launch Next-Generation Tetragraph System At Anesthesiology 2024 Conference

Second quarter 2024 earnings released

Senzime AB (publ.) Announces European Patent Office Issues New Patent Protecting Unique Capabilities of the Senzime TetraGraph System

New minor risk - Profitability

Full year 2023 earnings released: kr1.45 loss per share (vs kr1.99 loss in FY 2022)

Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Full year 2023 earnings released: kr1.45 loss per share (vs kr1.99 loss in FY 2022)

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia Open

Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.74 loss in 3Q 2022)

Senzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

New major risk - Shareholder dilution

Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive Skin

No longer forecast to breakeven

Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable Sensor

Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection Algorithm

Less than half of directors are independent

No longer forecast to breakeven

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

First quarter 2023 earnings released: kr0.42 loss per share (vs kr0.33 loss in 1Q 2022)

Less than half of directors are independent

Independent Chairman recently bought €66k worth of stock

Less than half of directors are independent

Senzime Receives Approval for Its Pediatric Sensor in Japan

Full year 2022 earnings released: kr1.99 loss per share (vs kr1.31 loss in FY 2021)

Senzime AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023

Senzime Receives First Contract for TetraSens Pediatric in the US

Less than half of directors are independent

Senzime's TetraGraph supported by new European clinical guidelines for patient monitoring

Senzime AB (publ) Provides Earnings Guidance for 2025

Senzime AB (Publ) Announces Board Appointments

Senzime AB (publ) Receives FDA 510K-Clearance for New Disposable Sensor Intended for Monitoring of Children

Senzime AB (publ) Announces Launch of TetraGraph Xcom Interface to Electronic Medical Records

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: kr0.63 loss per share (vs kr0.35 loss in 2Q 2021)

Less than half of directors are independent

Senzime AB (publ) (OM:SEZI) entered into an agreement to acquire Respiratory Motion, Inc. for $44 million.

First quarter 2022 earnings released: kr0.33 loss per share (vs kr0.27 loss in 1Q 2021)

Less than half of directors are independent

Senzime AB (Publ) Applies for FDA Approval for A New Single-Use Sensor for Children

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Senzime Announces Anesthesia Patient Safety Foundation Recommends Use of A Quantitative Monitor Whenever A Neuromuscular Blocking Agent Is Administered

Senzime AB (Publ) Announces Japanese Study Confirms Tetragraph Monitor as a Better Indicator of Appropriate Reversal Dose of Sugammadex and Adequate Recovery of Neuromuscular Function Than Amg-Based Tof- Watch SX

Third quarter 2021 earnings released: kr0.31 loss per share (vs kr0.20 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.35 loss per share (vs kr0.23 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.27 loss per share (vs kr0.17 loss in 1Q 2020)

Senzime AB (publ) Appoints Eva Walde as New Member of the Board of Directors

Full year 2020 earnings released: kr0.84 loss per share (vs kr0.68 loss in FY 2019)

Senzime AB (publ) to Report Q3, 2021 Results on Nov 12, 2021

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven